MedTrace Logo

Behavioral Treatment, Drug Treatment, and Combined Treatment for Attention Deficit Hyperactivity Disorder (ADHD)

NCT00050622 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 154

Last updated 2016-09-30

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the effectiveness of behavioral treatment, drug treatment, and combined treatment for children with Attention Deficit Hyperactivity Disorder (ADHD). This study will also examine the interactions between different levels of behavioral and drug treatments.

Conditions

  • Attention Deficit Disorder With Hyperactivity

Interventions

DRUG

Methylphenidate 0.15 mg/kg

0.15 m/kg/dose immediate-release methylphenidate

BEHAVIORAL

Low-Intensity BMOD

Lower-intensity behavioral treatment package.

DRUG

Methylphenidate 0.3 mg/kg

0.3 mg/kg/dose immediate-release methylphenidate

DRUG

Placebo

DRUG

Methylphenidate 0.6 mg/kg

0.3 mg/kg/dose immediate-release methylphenidate

BEHAVIORAL

High Intensity BMOD

Comprehensive high-intensity Summer Treatment Program (STP)

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • Florida International University

    lead OTHER

Principal Investigators

  • William E Pelham, PhD · Professor, Florida International University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
5 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-09-30
Primary Completion
2004-08-31
Completion
2005-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00050622 on ClinicalTrials.gov